Earnings

Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate

Aug 14, 2026 · 05:07 PM ET· updated 3h ago

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 57.5 percent increase over losses of $(0.80) per share from the

Why It Matters

Citius Pharma lost less money per share than people expected, which is good. But the company made way less money from selling stuff than hoped for, which shows the business is still struggling.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CTXR0.69

-0.05 (-6.62%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.